HER-2阳性乳腺癌靶向药物治疗的研究进展

曹晓珊; 丛斌斌

doi:10.3969/j.issn.1000-8179.2019.18.945

HER-2阳性乳腺癌靶向药物治疗的研究进展

doi: 10.3969/j.issn.1000-8179.2019.18.945

曹晓珊,
丛斌斌^,

山东第一医科大学(山东省医学科学院), 山东省肿瘤防治研究院(山东省肿瘤医院)乳腺病中心(济南市 250117)

详细信息

作者简介:
曹晓珊专业方向为乳腺疾病基础与临床相关研究。E-mail:caoxiaoshan2009@163.com

通讯作者:
丛斌斌 congbinbinbin@126.com

计量
- 文章访问数: 237
- HTML全文浏览量: 11
- PDF下载量: 18
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-10
- 刊出日期: 2019-09-30

The progress of targeted agents for HER-2 positive breast cancer

Cao Xiaoshan,
Cong Binbin^,

Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, China

More Information

Corresponding author: Binbin Cong; E-mail:congbinbinbin@126.com

摘要

摘要: 人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）阳性乳腺癌占全部乳腺癌分子类型的15%~20%，该类型乳腺癌恶性程度高，预后差。抗HER-2靶向药物能有效降低这部分乳腺癌复发和转移的风险，延长患者生存，并改善预后。目前多种抗HER-2靶向药物（如帕妥珠单抗、T-DM1、吡咯替尼等）相继问世，使乳腺癌治疗策略不断优化，为HER-2阳性乳腺癌提供更精准的治疗方案。本文针对HER-2阳性乳腺癌靶向药物治疗的最新研究结果进行相关综述。
- 乳腺癌 /
- 人表皮生长因子受体-2 /
- 靶向药物
Abstract: Human epidermal growth factor receptor-2 (HER-2) gene amplification and protein overexpression occur in approximately 15% to 20% of breast cancer patients, resulting in a clinically aggressive tumor type that is associated with a poor prognosis. HER-2-targeted therapies could effectively reduce the recurrence and improve the prognosis of breast cancer. In recent years, the application of new anti-HER-2 agents, such as pertuzumab, T-DM1, and pyrotinib, have further improved the survival of patients with HER2-positive breast cancer, and updated the guidelines for the treatment of breast cancer, making anti-HER-2 targeted therapy more accurate. This review described the latest development of targeted agents for HER-2-positive breast cancer.
- breast cancer /
- human epidermal growth factor receptor-2 (HER-2) /
- targeted agent

HTML全文

参考文献(22)

[1]	Scheuer W, Friess T, BurtscherH, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models[J]. Cancer Res, 2009, 69(24):9330-9336. doi: 10.1158/0008-5472.CAN-08-4597
[2]	Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' followup of trastuzumab after adjuvant chemotherapy in HER-2 positive early breast cancer:final analysis of the HERceptin adjuvant (HERA) trial[J].Lancet, 2017, 389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2
[3]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER-2 positive breast cancer[J]. N Engl J Med, 2011, 365(14):1273-1283. doi: 10.1056/NEJMoa0910383
[4]	Howie LJ, Scher NS, Amiri-Kordestani L, et al. FDA approval summary:pertuzumab for adjuvant treatment of HER-2 positive early breast cancer[J]. Clin Cancer Res, 2019, 25(10):2949-2955. doi: 10.1158/1078-0432.CCR-18-3003
[5]	Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast caner[J]. N Engl J Med, 2012, 366(2):109-119. doi: 10.1056/NEJMoa1113216
[6]	Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN):a randomized, open-label phase Ⅱ trial[J]. J Clin Oncol, 2018, 36(28):2826-2835. doi: 10.1200/JCO.2017.76.7863
[7]	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER-2 positive breast cancer (NeoSphere):a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7
[8]	张毅.第41届美国圣安东尼奥乳腺癌研讨会重要研究进展解析[J].中华乳腺病杂志(电子版), 2019, 13(3):129-136. doi: 10.3877/cma.j.issn.1674-0807.2019.03.001
[9]	Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase Ⅱ TRYPHAENA cardiac safety study:evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER-2 positive early breast cancer[J]. Eur J Cancer, 2018, 89:27-35. doi: 10.1016/j.ejca.2017.10.021
[10]	von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER-2 positive breast cancer[J]. N Engl J Med, 2017, 377(2):122-131. doi: 10.1056/NEJMoa1703643
[11]	Bang YJ, Giaccone G, Im SA, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER-2 positive advanced solid tumors[J]. Ann Oncol, 2017, 28(4):855-861. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=eac93301e6c61d9cb09044d5093262ae
[12]	Viale G, Morganti S, Ferraro E, et al. What therapies are on the horizon for HER-2 positive breast cancer[J]? Expert Rev Anticancer Ther, 2019, 19(9):811-822. doi: 10.1080/14737140.2019.1660164
[13]	Recondo G Jr, de la Vega M, Galantemik F, et al. Novel approaches to target HER-2positive breast cancer:trastuzumab emtansine[J]. Cancer Manag Res, 2016, 8:57-65. http://cn.bing.com/academic/profile?id=95621685d1568b7be080ec1cba22f278&encoded=0&v=paper_preview&mkt=zh-cn
[14]	Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER-2 positive advanced breast cancer (EMILIA):a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1
[15]	Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER-2 positive metastatic breast cancer (TH3RESA):final overall survival results from a randomised open-label phase 3 trial[J]. Lancet Oncol, 2017, 18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3
[16]	von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER-2 positive breast cancer[J]. N Engl J Med, 2019, 380(7):617-628. doi: 10.1056/NEJMoa1814017
[17]	Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer:three-year outcomes from the phase Ⅲ KRISTINE study[J]. J Clin Oncol, 2019, 37(25):2206-2216. doi: 10.1200/JCO.19.00882
[18]	Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib[J]. Recent Results Cancer Res, 2018, 211:19-44. http://d.old.wanfangdata.com.cn/Periodical/gwyx-zlxfc200708012
[19]	Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER-2positive breast cancer (ExteNET):5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9
[20]	Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer[J]. N Engl J Med, 2016, 375(1):11-22. doi: 10.1056/NEJMoa1513750
[21]	Li Q, Guan X, Chen S, et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER-2 positive metastatic breast cancer patients:a phase Ⅰ clinical trial[J]. Clin Cancer Res, 2019, 25(17):5212-5220. doi: 10.1158/1078-0432.CCR-18-4173
[22]	Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER-2 positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab:a randomized, phase Ⅱ study[J]. J Clin Oncol, 2019, 37(29):2610-2619. doi: 10.1200/JCO.19.00108